AU2020337883B2 - Heterocyclic pyrazole derivatives as type III receptor tyrosine kinase inhibitors - Google Patents
Heterocyclic pyrazole derivatives as type III receptor tyrosine kinase inhibitorsInfo
- Publication number
- AU2020337883B2 AU2020337883B2 AU2020337883A AU2020337883A AU2020337883B2 AU 2020337883 B2 AU2020337883 B2 AU 2020337883B2 AU 2020337883 A AU2020337883 A AU 2020337883A AU 2020337883 A AU2020337883 A AU 2020337883A AU 2020337883 B2 AU2020337883 B2 AU 2020337883B2
- Authority
- AU
- Australia
- Prior art keywords
- indazol
- dihydrothieno
- cyclopenta
- methyl
- methy1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962891097P | 2019-08-23 | 2019-08-23 | |
| US62/891,097 | 2019-08-23 | ||
| PCT/US2020/047552 WO2021041276A1 (en) | 2019-08-23 | 2020-08-22 | Heterocyclic pyrazole derivatives as type iii receptor tyrosine kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2020337883A1 AU2020337883A1 (en) | 2022-03-24 |
| AU2020337883B2 true AU2020337883B2 (en) | 2025-08-28 |
Family
ID=74685735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020337883A Active AU2020337883B2 (en) | 2019-08-23 | 2020-08-22 | Heterocyclic pyrazole derivatives as type III receptor tyrosine kinase inhibitors |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12448394B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4017853A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7651557B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220051365A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114502553B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020337883B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022003383A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3151821A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022002062A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI759829B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021041276A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113278010A (zh) * | 2021-06-01 | 2021-08-20 | 中国科学院上海有机化学研究所 | 一类蛋白激酶降解剂及其用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130274255A1 (en) * | 2012-04-12 | 2013-10-17 | Development Center For Biotechnology | Heterocyclic pyrazole compounds, method for preparing the same and use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003234567A1 (en) * | 2002-05-15 | 2003-12-02 | Janssen Pharmaceutica N.V. | N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors |
| RU2425677C2 (ru) | 2005-01-21 | 2011-08-10 | Астекс Терапьютикс Лимитед | Соединения, предназначенные для использования в фармацевтике |
| EP1845974A1 (en) * | 2005-01-21 | 2007-10-24 | Astex Therapeutics Limited | Pharmaceutical compounds |
| BRPI0618011A2 (pt) * | 2005-10-28 | 2011-08-16 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente |
| WO2008045627A2 (en) | 2006-10-06 | 2008-04-17 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| CA2686378C (en) * | 2007-05-04 | 2012-07-24 | Irm Llc | Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors |
| CA2780892C (en) * | 2009-11-13 | 2017-02-14 | Genosco | Kinase inhibitors |
| GB201007286D0 (en) * | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| UY33801A (es) | 2010-12-13 | 2013-06-28 | Array Biopharma Inc | COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4IL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III |
| WO2013142382A1 (en) * | 2012-03-22 | 2013-09-26 | Genosco | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors |
| GB201205669D0 (en) * | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| US9938273B2 (en) | 2015-12-07 | 2018-04-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CN119792569A (zh) | 2018-01-10 | 2025-04-11 | 财团法人生物技术开发中心 | 抗体protac偶联物 |
-
2020
- 2020-08-21 TW TW109128678A patent/TWI759829B/zh active
- 2020-08-22 US US17/636,116 patent/US12448394B2/en active Active
- 2020-08-22 CN CN202080059010.6A patent/CN114502553B/zh active Active
- 2020-08-22 CA CA3151821A patent/CA3151821A1/en active Pending
- 2020-08-22 WO PCT/US2020/047552 patent/WO2021041276A1/en not_active Ceased
- 2020-08-22 KR KR1020227009059A patent/KR20220051365A/ko active Pending
- 2020-08-22 AU AU2020337883A patent/AU2020337883B2/en active Active
- 2020-08-22 MX MX2022002062A patent/MX2022002062A/es unknown
- 2020-08-22 EP EP20856905.3A patent/EP4017853A4/en active Pending
- 2020-08-22 BR BR112022003383A patent/BR112022003383A2/pt unknown
- 2020-08-22 JP JP2022511322A patent/JP7651557B2/ja active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130274255A1 (en) * | 2012-04-12 | 2013-10-17 | Development Center For Biotechnology | Heterocyclic pyrazole compounds, method for preparing the same and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114502553A (zh) | 2022-05-13 |
| WO2021041276A1 (en) | 2021-03-04 |
| EP4017853A4 (en) | 2023-08-30 |
| US12448394B2 (en) | 2025-10-21 |
| MX2022002062A (es) | 2022-04-25 |
| TWI759829B (zh) | 2022-04-01 |
| AU2020337883A1 (en) | 2022-03-24 |
| CN114502553B (zh) | 2024-07-26 |
| TW202115087A (zh) | 2021-04-16 |
| EP4017853A1 (en) | 2022-06-29 |
| CA3151821A1 (en) | 2021-03-04 |
| US20220289759A1 (en) | 2022-09-15 |
| KR20220051365A (ko) | 2022-04-26 |
| JP7651557B2 (ja) | 2025-03-26 |
| BR112022003383A2 (pt) | 2022-05-17 |
| JP2022545019A (ja) | 2022-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107922431B (zh) | Hpk1抑制剂及其使用方法 | |
| JP5871896B2 (ja) | B−rafキナーゼインヒビター | |
| JP2025118762A (ja) | ヘテロアリールアミノピリミジンアミドオートファジー阻害剤およびその使用方法 | |
| JP2024102236A (ja) | Prmt5阻害剤 | |
| CN117062818A (zh) | 新型sos1抑制剂及其制备方法和应用 | |
| JP5863058B2 (ja) | 1H−イミダゾ[4,5−c]キノリン | |
| WO2018177403A1 (zh) | 1H-咪唑[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂 | |
| TW202521536A (zh) | Cdk抑制劑 | |
| JP2021514373A (ja) | Egfr阻害剤としての新たなベンズイミダゾール化合物および誘導体 | |
| EP2646432A1 (en) | Substituted benzopyrazin derivatives as fgfr kinase inhibitors for the treatment of cancer diseases | |
| CN111072645B (zh) | 作为TGF-βR1抑制剂的化合物及其应用 | |
| AU2017342928A1 (en) | Quinoxaline compounds as type III receptor tyrosine kinase inhibitors | |
| CA3078942A1 (en) | Pyrrolotriazine compounds and methods of inhibiting tam kinases | |
| US12448394B2 (en) | Heterocyclic pyrazole derivatives as type III receptor tyrosine kinase inhibitors | |
| CA2946990A1 (en) | Heterocyclic compounds and their use as dopamine d1 ligands | |
| AU2024284667A1 (en) | Pyrazolo-pyrimidinone compounds for use in methods of inhibiting wee1 a kinase | |
| RU2833004C2 (ru) | Производные гетероциклического пиразола как ингибиторы рецепторной тирозикиназы типа III | |
| HK40057478B (en) | Hpk1 inhibitors and methods of using same | |
| WO2025113625A1 (zh) | 作为pkmyt1抑制剂的杂芳环和杂双环化合物及其应用 | |
| WO2026102147A1 (en) | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders | |
| CA3211149A1 (en) | Pharmaceutical compound | |
| HK40057478A (en) | Hpk1 inhibitors and methods of using same | |
| HK40043317A (en) | COMPOUND AS TGF-β R1 INHIBITOR AND APPLICATION THEREOF |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |